Therapeutic potential of peptide deformylase inhibitors

Bibliography

• MARTIN JM, GREEN M, KA, WALD ER: Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J. Med. (2002) 346:1200–1206.
   PubMed Web of Science ®Google Scholar
• GIGLIONE C, PIERRE M, MEINNEL T: Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol Microbia (2000) 36:1197–1205.
   PubMed Web of Science ®Google Scholar
• ••The first review on PDF as an antibacterialdrug discovery target.
   Google Scholar
• YUAN Z, TRIAS J, WHITE RJ: Deformylase as a novel antibacterial target. Drug Discov. Today (2001) 6:954–961.
   PubMed Web of Science ®Google Scholar
• CLEMENTS JM, AYSCOUGH A, KEAVEY K, EAST SP: Peptide deformylase inhibitors, potential for a new class of broad spectrum antibacterials. Cuff. Med. Chem. (2002) 1:239–249.
   Google Scholar
• BOULAROT A, GIGLIONE C, ARTAUD I, MEINNEL T: Structure-activity relationship analysis and therapeutic potential of peptide deformylase inhibitors. Cuff. Opin. Investzg Drugs (2004) 5:809–822.
   PubMedGoogle Scholar
• JAIN R, CHEN D, WHITE RJ, PATEL DV, YUAN Z: Bacterial Peptide Deformylase Inhibitors: A New Class of Antibacterial Agents. Cuff. Med. Chem. (2005) 12:1606–1621.
   Web of Science ®Google Scholar
• ••The most recent comprehensive review onPDF inhibitors with many useful tables.
   Google Scholar
• LEVITON I: Inhibitors of protein synthesis. Cancer Invest. (1999) 17:87–92.
   PubMed Web of Science ®Google Scholar
• MAZEL D, COIC E, BLANCHARD S, SAURIN W, MARLIERE P: A survey of polypeptide deformylase function throughout the eubacterial lineage. J. Mol Biol (1997) 266:939–949.
   PubMed Web of Science ®Google Scholar
• MAZEL D, POCHET S, MARLIERE P: Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J. (1994) 13:914–923.
   PubMed Web of Science ®Google Scholar
• ADAMS JM, CAPECCHI MR: N-formylmethionyl-sRNA as the initiator of protein synthesis. Proc. Natl. Acad. Sci. USA (1966) 55:147–155.
   PubMed Web of Science ®Google Scholar
• ADAMS JM: On the release of the formylgroup from nascent protein. J. Mol Biol. (1968) 33:571–589.
   PubMed Web of Science ®Google Scholar
• MEINNEL T, MECHULAIVI Y, BLANQUET S: Methionine as translation start signal: a review of the enzymes of the pathway in Escherichia coli. Biochimie (1993) 75:1061–1075.
   PubMed Web of Science ®Google Scholar
• GROCHE D, BECKER A. SCHLICHTING I, KABSCH W, SCHULTZ S, WAGNER AF: Isolation and crystallization of functionally competent Escherichia coli peptide deformylase forms containing either iron or nickel in the active site. Biochem. Biophys. Res. Comm. (1998) 246:342–346.
   PubMed Web of Science ®Google Scholar
• RAGUSA S, BLANQUET S, MEINNELT: Control of peptide deformylase activity by metal cations. Mo/. Bid. (1998) 280:515–523.
   PubMed Web of Science ®Google Scholar
• MEINNEL T, BLANQUET S: Characterization of the Thermus thermophilus locus encoding peptide deformylase and methionyl-tRNA (fMet) formyltransferase. J. Bacteria (1994) 176:7387–7390.
   PubMed Web of Science ®Google Scholar
• RAJAGOPALAN PTR, YU XC, PEI D: Peptide deformylase, a new type of maononuclear iron protein. J. Am. Chem. Soc. (1997) 119:12418–12419.
   Web of Science ®Google Scholar
• RAJAGOPALAN PT, PEI D: Oxygen-mediated inactivation of peptide deformylase. J. Biol. Chem. (1998) 273:22305–22310.
   PubMed Web of Science ®Google Scholar
• MARGOLIS PS, HACKBARTH CJ, YOUNG DC et al.: Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Anti microb. Agents Chemother. (2000) 44:1825–1831.
   PubMed Web of Science ®Google Scholar
• •This study reveals that, under selection pressure, some bacteria, such as S. aureus, can eliminate the formylation function in order to bypass the need for deformylase activity.
   Google Scholar
• MEINNEL T, LAZENNEC C, S, BLANQUET S: Structure-function relationships within the peptide deformylase family. Evidence for a conserved architecture of the active site involving three conserved motifs and a metal ion. J. Md. Biol. (1997) 267:749–761.
   Google Scholar
• NEWTON DT, CREUZENET C, MANGROO D: Formylation is not essential for initiation of protein synthesis in all eubacteria. J. Biol. Chem. (1999) 274:22143–22146.
   PubMed Web of Science ®Google Scholar
• MEINNEL T: Peptide deformylase of eukaryotic protists: a target for new agents? Parasitol. Today (2000) 16:165–168.
   Google Scholar
• BRACCHI-RICARD V, NGUYEN KT, ZHOU Y, RAJAGOPALAN PT, CHAKRABARTI D, PEI D: Characterization of an eukaryotic peptide deformylase from Plasmodium falciparum. Arch. Biochem. Biophys. (2001) 396:162–170.
   PubMed Web of Science ®Google Scholar
• NGUYEN KT, HU X, COLTON C, CHAKRABARTI R, ZHU MX, PEI D: Characterization of a human peptide deformylase: implications for antibacterial drug design. Biochemistry (2003) 42:9952–9958.
   PubMed Web of Science ®Google Scholar
• •Discovery of human PDF.
   Google Scholar
• LEE MD, ANTCZAK C, LI Y, SIROTNAK FM, BORNMANN WG, SCHEINBERG DA: A new human peptide deformylase inhibitable by actinonin. Biochem. Biophys. Res. Comm. (2003) 312:309–315.
   PubMed Web of Science ®Google Scholar
• SERERO A, GIGLIONE C, SARDINI A, MARTINEZ-SANZ J, MEINNEL T: An unusual peptide deformylase features in the human mitochondrial N-terminal methionine excision pathway. J. Biol. Chem. (2003) 278:52953–52963.
   PubMed Web of Science ®Google Scholar
• MEINNEL T, BLANQUET S, F: A new subclass of the zinc metalloproteases superfamily revealed by the solution structure of peptide deformylase. J. Mot Bid. (1996) 262:375–386.
   PubMed Web of Science ®Google Scholar
• CHAN MK, GONG W, PT, HAO B, TSAI CM, PEI D: Crystal structure of the Escherichia coli peptide deformylase [published erratum appears in Biochemistry (1998) 37(37):13042]. Biochemistry (1997) 36:13904–13909.
   PubMed Web of Science ®Google Scholar
• DARDEL F, RAGUSA S, LAZENNEC C, BLANQUET S, MEINNEL T: Solution structure of nickel-peptide deformylase. Mo/. Bid. (1998) 280:501–513.
   PubMed Web of Science ®Google Scholar
• GUILLOTEAU JP, MATHIEU M, GIGLIONE C et al.: The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: a platform for the structure-based design of antibacterial agents. J. MoL Biol. (2002) 320:951–962.
   PubMed Web of Science ®Google Scholar
• APFEL C, BANNER DW, BUR D et al.: Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J. Med. Chem. (2000) 43:2324–2331.
   PubMed Web of Science ®Google Scholar
• CLEMENTS JM, BECKETT RP, BROWN A et al.: Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. (2001) 45:563–570.
   PubMed Web of Science ®Google Scholar
• HACKBARTH CJ, CHEN DZ, LEWIS JG et al.: N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother. (2002) 46:2752–2764.
   PubMed Web of Science ®Google Scholar
• CHEN DZ, PATEL DV, CJ et al.: Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry (2000) 39:1256–1262.
   PubMed Web of Science ®Google Scholar
• ••This study suggest that PDF inhibitor,such as actinonin, can inhibit bacterial growth through the inhibition of deformylation.
   Google Scholar
• VAN ALLER GS, NANDIGAMA R, PETIT CM et al.: Mechanism of time-dependent inhibition of polypeptide deformylase by actinonin. Biochemistry (2005) 44:253–260.
   PubMed Web of Science ®Google Scholar
• JONES RN, RHOMBERG PR: Comparative spectrum and activity of NVP-PDF386 (VRC-4887), a new peptide deformylase inhibitor. J. Antimicrob. Chemother. (2003) 51:157–161.
   PubMed Web of Science ®Google Scholar
• LOFLAND D, DIFUNTORUM S, WALLER A et al.: In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698.1 Antimicrob. Chemother. (2004) 53:664–668.
   Google Scholar
• BOWKER KE, NOEL AR, AP: In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens. Int. J. Antimicrob. Agents (2003) 22:557–561.
   PubMed Web of Science ®Google Scholar
• CREDITO K, LIN G, EDNIE LM, APPELBAUM PC: Antistaphylococcal activity of LBM-415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob. Agents Chemother. (2004) 48:4033–4036.
   PubMed Web of Science ®Google Scholar
• EDNIE LM, PANKUCH G, APPELBAUM PC: Antipneumococcal activity of LBM-415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob. Agents Chemother. (2004) 48:4027–4032.
   PubMed Web of Science ®Google Scholar
• ROBLIN PM, HAMMERSCHLAG MR: In vitro activity of a new antibiotic, NVP-PDF386 (VRC-4887), against Chlamydia pneumoniae. Antimicrob. Agents Chemother. (2003) 47:1447–1448.
   PubMed Web of Science ®Google Scholar
• FRITSCHE TR, MOET GJ, JONES RN: Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM-415), a novel inhibitor of bacterial peptide deformylase. Clin. Microbiol Infect. (2004) 10:857–860.
   PubMed Web of Science ®Google Scholar
• FRITSCHE TR, SADER HS, R, JONES RN: Comparative antimicrobial characterization of LBM-415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob. Agents Chemother. (2005) 49:1468–1476.
   PubMed Web of Science ®Google Scholar
• •This publication discusses the in vitro antibacterial activity of the deformylase inhibitor LBM-415 (VIC–104959).
   Google Scholar
• MARGOLIS P, HACKBARTH C, LOPEZ S et al.: Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB. Antimicrob. Agents Chemother. (2001) 45:2432–2435.
   PubMed Web of Science ®Google Scholar
• APFEL CM, LOCHER H, EVERS S et al.: Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. (2001) 45:1058–1064.
   PubMed Web of Science ®Google Scholar
• NOEL AR, BOWKER KE, HOWE RA, MacGOWAN AP: Emergence of resistance in S. pneumoniae to peptide deformylase inhibitors in comparison to fluoroquinolones. 42th Annual ICAAC Meeting, San Diego, USA (2002) (Abstract F–1680).
   Google Scholar
• BOZDOGAN B, ESEL D, C, BROWNE FA, APPELBAUM PC: Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. (2003) 52:864–868.
   PubMed Web of Science ®Google Scholar
• LOPEZ S, WU C, BLAIS J et al.: In vitro profiling of the new peptide deformylase inhibitor LBM-415 (VIC-104959). 44th Annual ICAAC Meeting, Washington DC, USA (2004) (Abstract F1960).
   Google Scholar
• CHEN D, HACKBARTH C, NI ZJ et al.: Peptide deformylase inhibitors as antibacterial agents: identification of VRC-3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach. Antimicrob. Agents Chemother. (2004) 48:250–261.
   PubMed Web of Science ®Google Scholar
• CLEMENTS JM, BECKETT P, CATLIN G et al.: In vitro and in vivo antibacterial activity of the peptide deformylase inhibitor BB-3497. 40th Annual ICAAC Meeting, Toronto, Canada (2000) (Abstract 2177).
   Google Scholar
• GROSS M, CLEMENTS JM, P et al.: Oral anti- activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. (2004) 53:487–493.
   Web of Science ®Google Scholar
• WIESNER J, SANDERBRAND S, ALTINCICEK B, BECK E, JOMAA H: Seeking new targets for antiparasitic agents. Trends Parasitol (2001) 17:7–8.
   PubMed Web of Science ®Google Scholar
• WIESNER J, SEEBER F: The plastid-derived organelle of protozoan human parasites as a target of established and emerging drugs. Expert Opin. Ther. Targets (2005) 9:23–44.
   PubMed Web of Science ®Google Scholar
• XU Y, LAI LT, GABRILOVE JL, SCHEINBERG DA: Antitumor activity of actinonin in vitro and in vivo. Clin. Cancer Res. (1998) 4:171–176.
   PubMed Web of Science ®Google Scholar
• LEE MD, SHE Y, SOSKIS MJ et al.: Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. J. Clin. Invest. (2004) 114:1107–1116.
   PubMed Web of Science ®Google Scholar
• RAMANATHAN-GIRISH S, McCOLM J, CLEMENTS JM et al.: Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob. Agents Chemother. (2004) 48:4835–4842.
   PubMed Web of Science ®Google Scholar
• ••An excellent summary of in vivo predinicalstudies and Phase I clinical study for the deformylase inhibitor BB-83698.
   Google Scholar
• AZOULAY-DUPUIS E, MOHLER J, BEDOS JP: Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia. Antimicrob. Agents Chemother. (2004) 48:80–85.
   PubMed Web of Science ®Google Scholar
• CRAIG W, ANDES D: In vivo pharmocodynamics of BB-83698, a deformylase inhibitor. 4Ith Annual ICAAC Meeting, Chicago, USA (2001) (Abstract F–355).
   Google Scholar
• JONES RN, FRITSCHE TR, SADER HS: Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates. Diagn. Microbiol Infect. Dis. (2004) 49:63–65.
   PubMed Web of Science ®Google Scholar
• NECKERMANN G, YU D, MANNI K et al.: LBM-415, a New Oral Peptide Deformylase Inhibitor: Efficacy in murine infection model. 44th Annual ICAAC Meeting, Washington DC, USA (2004) (Abstract F–1964).
   Google Scholar
• CHEN D, TEMBE V, CRAMER Get al.:LBM-415 (VIC-104959), a novel peptide deformylase inhibitor with favorable pharmacokinetic profile in rodents. 44th Annual ICAAC Meeting, Washington DC, USA (2004) (Abstract F–1965).
   Google Scholar
• OSBORNE C, NECKERMANN G, GOLDOVITZ J et al.: Pharmacodynamics of LBM415, a new peptide deformylase inhibitor, in the neutropenic mouse thigh Infection Model. 44th Annual ICAAC Meeting, Washington DC, USA (2004) (Abstract 1963).
   Google Scholar
• CRAIG W, ANDES D: In vivo pharmacodynamic activity of LBM415 against multiple bacterial pathogens. 14th European Congress of Clinical Microbiology Infectious Diseases. Prague, Czech Republic (2004) (Poster P–922).
   Google Scholar
• SUN H, MacLEOD C, ZHENG W, DOBSON C, SKERJANEC A: Single and multiple dose pharmacokinetics of LBM-415, a novel peptide deformylase inhibitor. 33rd Annual Meeting of American College of Clinical Pharmacology Phoenix, USA (2004).
   Google Scholar
• RYDER NS, DZINK-FOX J, KUBIK B et al.: LBM15, a new peptide deformylase inhibitor with potent in vitro activity against drug-resistant bacteria. 44th Annual ICAAC Meeting Washington DC, USA (2004) (Abstract F–1959).
   Google Scholar
• HACKBARTH CJ, LOPEZ S, WU C et al.: Activity of peptide deformylase (PDF) against Gram-negative bacteria, 43rd Annual ICAAC Meeting, Chicago, IL, USA (2003) (Abstract F–1479).
   Google Scholar
• BRACKEN K: Peptide deformylase inhibition: progress in development and lessons learned. 7th Annual Superbugs and Superdrugs Conference, London, UK, March 7 — 8 (2005).
   Google Scholar